Ustekinumab as Induction and Maintenance Therapy for Ulcerative ColitisBruce E. Sands, Colleen Marano, William J. Sandborn et al.|New England Journal of Medicine|2019Cited by 1.2k
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative ColitisWilliam J. Sandborn, Paul Rutgeerts, Brian G. Feagan et al.|Gastroenterology|2013Cited by 938
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative ColitisWilliam J. Sandborn, Paul Rutgeerts, Brian G. Feagan et al.|Gastroenterology|2013Cited by 725
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative ColitisOmoniyi J. Adedokun, Walter Reinisch, William J. Sandborn et al.|Gastroenterology|2014Cited by 339
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trialsGary Lichtenstein, William J. Sandborn, Robert H. Diamond et al.|Alimentary Pharmacology & Therapeutics|2009Cited by 195